Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.35 |
| ▸ | FLT1 | P17948 | 4/20 | 0.35 |
| ▸ | FLT4 | P35916 | 4/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL822592 | 0.99 | KDR (0.35) | KDRFLT1FLT4MAPK9MAPK10 | |
| SCHEMBL822731 | 0.89 | MAPK9 (0.43) | KDRFLT1FLT4MAPK9MAPK10 | |
| SCHEMBL822887 | 0.86 | KDR (0.41) | KDRFLT1FLT4MAPK9MAPK10 | |
| SCHEMBL822604 | 0.83 | P2RX4 (0.38) | KDRFLT1FLT4MAPK9MAPK10 | |
| SCHEMBL822584 | 0.79 | MAPK9 (0.39) | KDRFLT1FLT4MAPK9MAPK10 | |
| SCHEMBL822726 | 0.74 | MAPK9 (0.56) | KDRFLT1FLT4MAPK9MAPK10 | |
| SCHEMBL15315957 | 0.73 | KDR (0.43) | KDRFLT1FLT4MAPK9MAPK10 | |
| SCHEMBL28813675 | 0.73 | KDR (0.46) | KDRFLT1FLT4MAPK9MAPK10 | |
| SCHEMBL15316042 | 0.71 | KDR (0.42) | KDRFLT1FLT4MAPK9MAPK10 | |
| SCHEMBL15316093 | 0.70 | KDR (0.36) | KDRFLT1FLT4MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067919-B2 | Use of dibenzofurans and dibenzothiophenes substituted by nitrogen-bonded five-membered heterocyclic rings in organic electronics | BASF SE (DE) | 2015-06-30 | — | — | US | disclosed |
| US-20120007063-A1 | USE OF DIBENZOFURANS AND DIBENZOTHIOPHENES SUBSTITUTED BY NITROGEN-BONDED FIVE-MEMBERED HETEROCYCLIC RINGS IN ORGANIC ELECTRONICS | BASF SE (DE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120007063-A1 | USE OF DIBENZOFURANS AND DIBENZOTHIOPHENES SUBSTITUTED BY NITROGEN-BONDED FIVE-MEMBERED HETEROCYCLIC RINGS IN ORGANIC ELECTRONICS | DDT, DBF4, POU5F1 | KDR 1620/4885FLT1 4117/4885FLT4 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.